Questionable Benefit for Episiotomy in Vacuum Delivery

This article originally appeared here.
Share this content:
Questionable Benefit for Episiotomy in Vacuum Delivery
Questionable Benefit for Episiotomy in Vacuum Delivery

WEDNESDAY, July 15, 2015 (HealthDay News) -- Episiotomy is associated with obstetric anal sphincter injuries (OASIS) during vacuum delivery, with risk varying based on parity and type of episiotomy, according to a meta-analysis published in the July issue of BJOG: An International Journal of Obstetrics and Gynaecology.

Lena Sagi-Dain, M.D., from the Carmel Medical Center, and Shlomi Sagi, M.D., from the Bnai Zion Medical Center -- both in Haifa, Israel, conducted a systematic review and meta-analysis to examine the role of episiotomy on outcomes during vacuum deliveries. Fifteen articles were reviewed, with data for 350,764 vacuum deliveries.

The researchers found that in nulliparous women there was a nonsignificant correlation between mediolateral episiotomy and OASIS (odds ratio [OR], 0.68; 95 percent confidence interval [CI], 0.43 to 1.07), while an increased risk was seen in parous women (OR, 1.27; 95 percent CI, 1.05 to 1.53). In nulliparous and parous women, there was a significantly higher risk of OASIS with median episiotomy use (ORs, 5.11 and 89.4, respectively). In nulliparous women, lateral episiotomy correlated with significantly lower OASIS risk (OR, 0.59). Increased rates of postpartum hemorrhage and analgesia use were seen in association with mediolateral episiotomy (ORs, 1.82 and 2.10, respectively).

"Mediolateral and median episiotomy in parous woman may increase the rate of OASIS at vacuum delivery, whereas lateral episiotomy in nulliparous women could be associated with a decreased risk of OASIS," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »